8th Targeted Radiopharmaceuticals (TRP) Summit Europe 2026

The 8th Targeted Radiopharmaceuticals (TRP) Summit Europe 2026 examines the scientific, clinical, and commercial progress of targeted radiopharmaceuticals, highlighting innovations in radioligand therapy, isotope selection, regulatory harmonization, and global commercialization strategies.

Key Topics

• Engineering smarter radioligands through optimized molecule and isotope pairing
• Evaluating the progress of targeted radiopharmaceuticals across Europe and beyond
• Broadening target landscapes and advancing clinical applications
• Developing scalable isotope selection for commercial success
• Improving global supply chain management of radioisotopes and therapies
• Expanding TRP therapy into neuroendocrine tumours through new targeting approaches
• Understanding international procedures and regulations for global harmonization
• Advancing innovation platforms for emerging targeted radiopharmaceutical therapies
• Comparing standard of care with or without 177Lu-DOTA-Rosopatamab in clinical research
• Enhancing commercial readiness and regulatory approval strategies
• Overcoming challenges in radioligand therapy development

Who should Attend

• Radiopharmaceutical developers and manufacturers
• Clinical researchers in oncology and nuclear medicine
• Regulatory and compliance professionals
• Pharmaceutical and biotechnology executives
• Isotope production and supply chain specialists
• Academic scientists studying radiochemistry and molecular targeting
• Business development and commercialization experts in radiopharma